Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.74 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.74 |
| ▸ | PTPN11 | Q06124 | 10/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sipatrigine SCHEMBL29421474 | 0.85 | SCN2A (1.00) | SCN2AKCNK2PTPN11HRH4 | |
| SCHEMBL8576787 | 0.85 | SCN2A (0.74) | SCN2AKCNK2PTPN11 | |
| Sipatrigine SCHEMBL135888 | 0.85 | SCN2A (1.00) | SCN2AKCNK2PTPN11HRH4 | |
| SCHEMBL7280623 | 0.82 | SCN2A (0.73) | SCN2AKCNK2PTPN11SCN9A | |
| SCHEMBL7272688 | 0.82 | SCN2A (0.77) | SCN2AKCNK2PTPN11SCN9A | |
| SCHEMBL7273370 | 0.82 | SCN2A (0.77) | SCN2AKCNK2PTPN11SCN9A | |
| SCHEMBL7286933 | 0.81 | SCN2A (0.71) | SCN2AKCNK2PTPN11SCN9A | |
| SCHEMBL132945 | 0.80 | SCN2A (0.77) | SCN2AKCNK2PTPN11SCN9A | |
| SCHEMBL7272635 | 0.80 | PTPN11 (0.72) | SCN2AKCNK2PTPN11SCN9ABCL6 | |
| SCHEMBL7271253 | 0.78 | KCNK2 (0.67) | SCN2AKCNK2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229873-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2004-11-18 | — | — | US | claimed |
| US-20140079757-A1 | ORAL DRUG DELIVERY FORMULATIONS | BROWN RUDNICK LLP | 2014-03-20 | — | — | US | disclosed |
| WO-2012028963-A2 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | MS THERAPEUTICS LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| US-20120058097-A1 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | MS THERAPEUTICS LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058097-A1 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | CACNA1B, KCNMB1, KCNB2 | SCN2A 25/4885KCNK2 103/4885PTPN11 3117/4885 |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | CHRM2, CHRNA3, CHRNA2 | SCN2A 63/4885KCNK2 136/4885PTPN11 4876/4885 |
| US-20140079757-A1 | ORAL DRUG DELIVERY FORMULATIONS | PGF, MMP1, MMP26 | SCN2A 4830/4885KCNK2 3641/4885PTPN11 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.